The partnership will combine Daiichi Sankyo’s clinical trial and preclinical research data with Tempus’ real-world data.

Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today ...

Daiichi Sankyo Company (TSE:4568) has entered a collaboration with Tempus AI to apply AI models to patient selection and biomarker discovery in oncology. The company has also announced research ...

Daiichi Sankyo announces Enhertu now available in Japan as first ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer: Tokyo Wednesday, March 25, ...

Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug in certain European countries. The exclusive license and supply agreement ...

When Zymeworks and Daiichi Sankyo initially teamed up on bispecific antibodies in 2016, they kept the financial details under wraps. Now, the pair is entering a new license agreement that could ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr.

AstraZeneca is set to pay Daiichi Sankyo $1 billion to co-develop the antibody-drug conjugate (ADC) DS-1062 outside of Japan. The deal, which features a further $5 billion in milestones, represents a ...

TOKYO (Reuters) -Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese ...

After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion Japanese ...

Masahiro Kato takes over as Managing Director, Oliver Appelhans appointed to Head of the European Specialty Business Unit MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European ...